U.S. Tech Hardware Stock News

NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl Fund Close Highlights Asset Backed Credit And Valuation Debate

Blue Owl Capital (NYSE:OWL) has closed its Asset Special Opportunities Fund IX with about US$2.9b in capital commitments. The fund exceeded its original fundraising target at final close. The vehicle focuses on asset backed, opportunistic credit at a time of active discussion around private credit markets. For you as an investor, this fund close is a fresh data point on how Blue Owl Capital is positioned in private markets. The company is known for alternative asset management with a focus...
NasdaqGM:PNBK
NasdaqGM:PNBKBanks

Patriot National Bancorp (PNBK) Quarterly Loss Narrows To US$0.02 EPS Challenging Persistent Bearish Narratives

Patriot National Bancorp (PNBK) just closed out FY 2025 with fourth quarter revenue of US$9.8 million and a basic EPS loss of US$0.02, alongside trailing twelve month revenue of US$28.1 million and a basic EPS loss of US$0.17. Over recent quarters the company has seen revenue move from US$4.7 million in Q2 2025 to US$7.6 million in Q3 2025 and then to US$9.8 million in Q4 2025. Quarterly basic EPS losses narrowed from US$0.21 in Q1 2025 to US$0.06 in Q2, US$0.03 in Q3 and US$0.02 in Q4...
NasdaqGS:VC
NasdaqGS:VCAuto Components

Is Visteon (VC) Rewriting Its Cockpit Electronics Story With Softer 2026 Guidance?

In recent days, Visteon reported mixed fourth-quarter results, with revenue exceeding expectations while earnings and full-year guidance, including softer 2026 revenue and EBITDA forecasts, fell short of analyst estimates. Analysts have largely maintained positive ratings despite trimming some expectations, highlighting investors’ focus on how Visteon balances growth in digital cockpit and connected car solutions with more cautious longer-term guidance. Next, we’ll examine how Visteon’s...
NasdaqCM:ALTI
NasdaqCM:ALTICapital Markets

AlTi Global (ALTI) Swings To Q4 Profit And Tests Bullish Turnaround Narratives

AlTi Global (ALTI) closed out FY 2025 with fourth quarter revenue of US$88.3 million and basic EPS of US$0.08, while trailing twelve month figures show revenue of US$255.0 million and an EPS loss of US$1.23. Over the past reported periods, revenue has ranged from US$50.8 million to US$57.9 million across FY 2024 and early FY 2025 before stepping up to US$88.3 million most recently. Quarterly EPS has shifted between a profit of US$0.36 and a loss of US$0.69. For investors, the latest results...
NYSE:CI
NYSE:CIHealthcare

A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement

Recent analyst commentary around pharmacy benefit manager reform, a rebate-free model and a leadership change has put Cigna Group (CI) back in focus for investors watching how regulatory shifts shape earnings visibility. See our latest analysis for Cigna Group. Those regulatory updates and the CEO transition are playing out against a softer trading backdrop, with a 30 day share price return of an 8.09% decline and a 1 year total shareholder return of a 17.76% loss suggesting momentum has...
NYSE:DHI
NYSE:DHIConsumer Durables

D.R. Horton Expands Credit Capacity As Valuation And Momentum Diverge

D.R. Horton amended and expanded its primary credit facilities, lifting total capacity to $4b. The company extended maturities on these facilities, with certain lines now running through 2031. The changes affect D.R. Horton’s core liquidity resources and the terms under its main credit agreements. For investors tracking NYSE:DHI, this credit move comes with the stock trading around $138.25 and showing mixed recent performance. Shares are roughly 46.2% higher over 3 years and 57.7% over 5...
NasdaqCM:ANNA
NasdaqCM:ANNARenewable Energy

AleAnna (ANNA) Q3 Profit Of US$3.3 Million Tests Loss Making Narrative

AleAnna (NasdaqCM:ANNA) has just posted another quarter of rapid top line expansion, with Q3 FY 2025 revenue of about US$11.2 million and basic EPS of US$0.08, against a backdrop of very large revenue growth of 2,471.5% over the past year while remaining unprofitable on a trailing 12 month view. Over recent periods the company has seen revenue move from roughly US$0.6 million in Q3 FY 2024 to US$11.2 million in Q3 FY 2025, while trailing 12 month EPS across the last reported quarters stayed...
NYSE:IBM
NYSE:IBMIT

IBM FedRAMP AI Approval Puts Federal Growth And Valuation In Focus

International Business Machines (NYSE:IBM) has secured FedRAMP authorization for 11 AI and automation solutions. The approvals cover core watsonx offerings delivered via Amazon Web Services for US federal agencies. This authorization supports wider, more secure adoption of IBM's AI tools across highly regulated government environments. With a current share price of $243.14, International Business Machines sits at the intersection of long established enterprise relationships and newer AI...
NYSE:LVS
NYSE:LVSHospitality

Sands China Art Push Highlights Las Vegas Sands Valuation Debate

Sands China, a subsidiary of Las Vegas Sands, took part as an Associate Partner at Art Central in Hong Kong. It is the first integrated tourism and leisure enterprise from Macao to join the international art fair in this role. The participation highlights a move to support cultural tourism and local artists beyond traditional gaming activities. Las Vegas Sands (NYSE:LVS), trading at $54.32, is drawing attention not only for its resort assets but also for how it uses culture to attract...
NasdaqGS:KHC
NasdaqGS:KHCFood

Kraft Heinz Shelves Break Up To Test Core Turnaround Story

Kraft Heinz has cancelled its planned company break up after quietly ending merger talks with Unilever. New CEO Steve Cahillane is shifting focus to turning around the core business instead of pursuing large structural changes. The company plans to prioritize commercial growth, stabilizing volumes, and defending its brands in a competitive packaged food market. Kraft Heinz (NasdaqGS: KHC) is refocusing on its existing portfolio at a time when its share price sits at $22.27. The stock has...
NasdaqGS:UPST
NasdaqGS:UPSTConsumer Finance

A Look At Upstart Holdings (UPST) Valuation After Loan Growth Margin Gains And New Funding Deals

Upstart Holdings (UPST) is back in focus after reporting strong loan origination growth, rising operating margins, and a fresh forward flow deal that supports up to US$1b of consumer loan purchases. See our latest analysis for Upstart Holdings. Despite the upbeat loan origination and funding news, the 30 day share price return of 10.33% and year to date share price return of 44.68% are characterized as weak. The 1 year total shareholder return of 46.76% contrasts with a positive 3 year total...
NYSE:RH
NYSE:RHSpecialty Retail

RH (RH) Earnings Rebound And Margin Improvement Challenge Cautious Leverage Narratives

RH (RH) has wrapped up FY 2026 with fourth quarter revenue of US$842.6 million and basic EPS of US$1.53, capping a twelve month run where EPS on a trailing basis reached US$6.65 on revenue of about US$3.4 billion alongside a 72.4% year over year earnings recovery after several years of declines. Over the past eight quarters, revenue has moved from US$812.4 million in Q4 FY 2025 to US$842.6 million in Q4 FY 2026. Over the same period, quarterly EPS has ranged between US$0.75 and US$2.76 and...
NYSE:MSA
NYSE:MSACommercial Services

A Look At MSA Safety (MSA) Valuation After Recent Share Price Weakness

MSA Safety: Recent Returns Put Multi Year Run In Context MSA Safety (MSA) has attracted attention after a mixed run in its shares, with a negative month and past 7 days, set against positive returns over the past year and multi year periods. See our latest analysis for MSA Safety. At a share price of $166.35, MSA Safety has recently seen a 16.06% 1 month share price decline after a weaker 7 day period. However, the 1 year total shareholder return of 12.54% and 3 year total shareholder return...
NYSE:CE
NYSE:CEChemicals

Celanese Shelf Registration Adds Flexibility While Valuation Appears Depressed

Celanese Corporation (NYSE:CE) has filed an omnibus shelf registration with regulators. The filing allows the company to offer common stock, preferred stock, and debt securities over time. This structure gives Celanese the ability to raise capital when market conditions and funding needs align. Celanese produces specialty materials and chemicals used across sectors such as automotive, construction, and consumer goods, so access to flexible funding can matter for large projects or potential...
NYSE:DNOW
NYSE:DNOWTrade Distributors

Assessing DNOW (DNOW) Valuation As Iran Tensions Stir Concerns Over Global Energy Supply

Fresh geopolitical tension around President Trump’s threat to “completely obliterate” Iran’s energy infrastructure has pushed DNOW (DNOW) into focus, as investors weigh how potential supply disruptions could affect the distributor’s energy exposed business. See our latest analysis for DNOW. At a share price of $11.84, DNOW has recently seen weaker momentum, with a 90 day share price return of 10.64% and a 1 year total shareholder return of 31.60%. However, the 3 and 5 year total shareholder...
NYSE:UBER
NYSE:UBERTransportation

Has Uber Technologies (UBER) Share Price Weakness Opened A Long Term Opportunity

Wondering whether Uber Technologies at around US$71.71 is priced for opportunity or disappointment? This article walks through what the numbers are really saying about the stock’s value. The share price has seen a 1.9% decline over the last week, a 5.6% decline over the last month, and a 13.5% decline year to date, although the 3 year return sits at 130.4% and the 5 year return at 26.1%. These moves come as Uber continues to be a central name in ride hailing and delivery. Investors are...
NYSE:ASGN
NYSE:ASGNIT

Quinnox Deal and Everforth Rebrand Could Be A Game Changer For ASGN (ASGN)

In its latest quarter, ASGN reported revenue and adjusted EBITDA margins ahead of expectations but missed EPS forecasts, while also outlining integration of the Quinnox acquisition and a rebranding to Everforth to consolidate its seven brands. This combination of earnings mixed with margin outperformance and a pivot toward higher-value consulting and unified branding could meaningfully reshape ASGN’s business mix and competitive positioning over time. We’ll now examine how ASGN’s Quinnox...
NasdaqGS:IREN
NasdaqGS:IRENSoftware

Assessing IREN’s (NasdaqGS:IREN) Valuation After Its Multi Year US$9.7b Microsoft AI Contract

Microsoft contract puts IREN’s AI pivot in focus IREN (NasdaqGS:IREN) is drawing fresh attention after securing a multi year US$9.7b contract with Microsoft for dedicated liquid cooled GPU clusters, a deal that supports recurring, higher margin AI infrastructure revenue. See our latest analysis for IREN. Despite some recent volatility, including a 7 day share price return decline of 17.72% and a year to date share price return decline of 20.16%, IREN’s 1 year total shareholder return of...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

Assessing CoreWeave (CRWV) Valuation As Shares Show Mixed Short Term Performance

CoreWeave (CRWV) is drawing attention after recent trading, with the stock closing at $78.44 and showing mixed returns over the past week, month, and past 3 months as investors assess its cloud infrastructure business. See our latest analysis for CoreWeave. The 1 day share price return of 1.25% comes after a weaker 7 day share price return of 10.44%. The 1 year total shareholder return of 27.84% points to momentum that has built over a longer stretch despite recent volatility. If CoreWeave's...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

A Look At Nebius Group (NBIS) Valuation After Major AI Data Center Plan And Mega Tech Partnerships

Nebius Group (NasdaqGS:NBIS) is in focus after announcing a US$10b AI data center project in Lappeenranta, Finland, alongside large supply deals with Meta and Microsoft and a US$2b investment from Nvidia. See our latest analysis for Nebius Group. After a sharp rally recently, Nebius now trades at US$101.95, with a 30 day share price return of 12.02% and a year to date share price return of 13.34%. Its 1 year total shareholder return of 316.97% suggests very strong longer term momentum, while...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The data show durable efficacy across multiple clinical response thresholds and improvements in patient quality of life at 54 weeks. Safety results were consistent over the long term, supporting the overall benefit risk profile of povorcitinib in HS. This is the first publication of long-term pivotal data for povorcitinib in HS ahead of...
NYSE:ZIM
NYSE:ZIMShipping

How Expected Earnings and Revenue Pressure At ZIM Integrated Shipping Services (ZIM) Has Changed Its Investment Story

ZIM Integrated Shipping Services recently saw sentiment soften as investors reacted to projections for a substantial year-over-year decline in its upcoming quarterly earnings and revenue. The lack of recent changes in consensus earnings estimates, alongside a Hold rating on the Zacks scale, underscores lingering uncertainty over ZIM’s near-term operating outlook. Against this backdrop of expected earnings and revenue pressure, we will examine how this cautionary earnings setup could reshape...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Renewed Safe‑Haven Interest in Gold Might Change The Case For Investing In Gold.com (GOLD)

Recent commentary on Gold.com highlights how gold’s traditional role as a haven asset held firm despite a sharp price drop during the Middle East conflict, when liquidity needs temporarily pushed prices lower. The analysis points out that investors are now rebuilding gold exposure as concerns over global debt, currency debasement, and geopolitical risks persist, supporting renewed attention on the metal. We’ll now explore how persistent geopolitical and macroeconomic risks highlighted by...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative?

Zai Lab announced in the past that it will collaborate with Amgen on a global Phase 1b trial combining Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan with Amgen’s IMDELLTRA for patients with extensive-stage small cell lung cancer. Separately, the FDA’s identification of dozens of Tavneos-linked liver injury cases, including severe events and deaths, raises fresh questions about Amgen’s safety and regulatory risk profile. Next, we’ll explore how the FDA’s Tavneos safety concerns could...